Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts

Pediatric Nephrology

Volumn 24, Issue 3, 2009, Pages 571-579

  Bamgbola, Oluwatoyin Fatai ^a   Kaskel, Fredrick J ^b   Coco, Maria ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Age; Anemia; EPO resistance; Gender; Hemodialysis; Regression analysis

Indexed keywords

ERYTHROPOIETIN; FOLIC ACID; IRON; PARATHYROID HORMONE; UREA;

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; FOLIC ACID DEFICIENCY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; CHILD; COHORT STUDIES; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS;

EID: 59849129282     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0954-3     Document Type: Article

References (42)

1. Eschbach JW (1989) The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148
2. Marsh J, Brown W, Wolcott D, Carr C, Harper R, Schweitzer S, Nissenson A (1991) rHuEPO treatment improves brain and cognitive function in anemic dialysis patients. Kidney Int 39:155-163
3. Revicki D, Brown R, Feeny D, Henry D, Teehan B, Rudnick M, Benz R (1991) Health related quality of life with human erythropoietin treatment for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554
4. Di Iorio B, Cirillo M, Bellizzi V, Stellato D, De Santo NG (2007) Prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients: The Campania Dialysis Registry. Int J Artif Organs 30:325-333
5. Al-Hilali N, Al-Humoud H, Ninan VT, Nampoory MR, Puliyclil MA, Johny KV (2007) Does parathyroid hormone affect erythropoietin therapy in dialysis patients? Med Princ Pract 16:63-67
6. Seeherunvong W, Rubio L, Abitbol CL, Montane B, Strauss J, Diaz R, Zilleruelo G (2001) Identification of poor responders to erythropoietin among children undergoing hemodialysis. J Pediatr 138:710-714
7. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA (2000) Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 36:1166-1174
8. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM (2003) Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int 23:111-115
9. Bamgbola OF, Kaskel F (2005) Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 20:1622-1629
10. Health Care Financing Administration (1998) 1998 Annual Report, End-Stage Renal Disease Core Indicators Project. Baltimore MD, Department of Health and Human Services, HCFA, Office of Clinical Standards and Quality
11. Frankfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF Jr (1991) Racial/ethnic analysis of elected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 34:721-730
12. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA (2001) Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 38:518-522
13. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ (2004) Epoietin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866-876
14. Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H (1994) A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on hemodialysis. Pediatr Nephrol 8:338-342
15. Jabs K, Alexander S, McCabe D, Lerner G, Harmon WE (1994) Primary results from the US multicenter pediatric recombinant erythropoietin study. J Am Soc Nephrol 5:456-463
16. Palis J, Segel GB (1998) Developmental biology of erythropoiesis. Blood Rev 12:106-114
17. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM (2005) Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46:481-488
18. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH (2001) A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251-1263
19. El-Khatib M, Duncan HJ, Kant KS (2006) Role of C-reactive protein, reticulocyte hemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. Nephrology 11:400-404
20. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF (1999) The urea [clearance × dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int 56:729-737
21. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall C (2003) Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 14:1776-1784
22. Yuen D, Richardson RM, Fenton SS, McGrath-Chong ME, Chan CT (2005) Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. ASAIO J 51:236-241
23. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu PY, Yang CW (2002) Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 20:349-356
24. Gorman G, Furth S, Hwang W, Parekh R, Astor B, Fivush B, Frankenfield D, Neu A (2006) Clinical outcomes and dialysis adequacy in adolescent hemodialysis patients. Am J Kidney Dis 47:285-293
25. Chand DH, Brier M, Strife CF (2005) Comparison of vascular type in pediatric hemodialysis patients with respect to urea clearance, anemia management, and serum albumin concentration. Am J Kidney Dis 45:303-308
26. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ (2004) Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 66:2429-2436
27. Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Parrinello G, Cancarini GC (2006) The kind of vascular access influences the baseline inflammatory status and epoietin response in chronic hemodialysis patients. Blood Purif 24:387-393
28. Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM (2006) The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 16:64-68
29. Port RE, Kiepe D, Van Guilder M, Jellife RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: No justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57-70
30. Besarab A (2006) Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 69:S13-S18
31. Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266-273
32. Kato A, Hamada M, Suzuki T, Maruyama Y, Hishida A (2001) Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis. Nephron 89:110-112
33. Axelsson J, Qureshi AR, Heimbüger O, Lindholm B, Stenvikel P, Barany P (2005) Body fat mass and serum leptin levels influence epoietin sensitivity in patients with ESRD. Am J Kidney Dis 46:628-634
34. Nakamoto H, Kanno Y, Okada H, Suzuki H (2004) Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial 20:111-116
35. Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H (2003) The effect of high dose losartan on erythropoietin resistance in patients undergoing hemodialysis. Panminerva Med 45:59-62
36. Schaefer F, Veldhuis JD, Robertson WR, Dunger D, Scharer K (1994) Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure. Cooperative Study Group on Pubertal Development in Chronic Renal Failure. Kidney Int 45:1465-1476
37. Di Iorio BR, Stellato D, De Santo NG, Cirillo M (2004) Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 22:423-427
38. T'Sjoen GG, Beguin Y, Feyen E, Rubens R, Kaufman JM, Gooren L (2005) Influence of oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma. J Endocrinol 186:61-67
39. Zeng SM, Yankowitz J, Widness JA, Strauss RG (2001) Etiology of differences in hematocrit between males and females: Sequence-based polymorphisms in erythropoietin and its receptor. J Gend Specif Med 4:35-40
40. Hero M, Wickman S, Hanhijarvi R, Silmes MA, Dunkel L (2005) Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr 146:245-252
41. Le Petit-Thevenin J, Lerique B, Nobili O, Boyer J (1991) Estrogen modulates phospholipid acylation in red blood cells: Relationship to cell aging. Am J Physiol 261:C423-C427
42. Paoletti E, Cannella G (2006) Update on erythropoietin treatment: Should hemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol 17 [4 Suppl 2]:S74-S77